RSV vaccine player Codagenix snags $3M in public and private investment

12th October 2017 Uncategorised 0

Add a new contender to the list of companies aspiring to develop an effective respiratory syncytial virus (RSV) vaccine and nab a share of a potential multibillion-dollar market: Codagenix. The company just secured $3 million in funding from both public and private sources to advance its live-attenuated candidate.

More: RSV vaccine player Codagenix snags M in public and private investment
Source: fierce